Beijing Strong Biotechnologies (300406) Fundamentals 2026 — P/E 30.2x, Revenue Analysis | SniperIQ
Beijing Strong Biotechnologies (300406) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥6.6B, trading at ¥11.19 on the SHZ. This SniperIQ fundamentals page covers Beijing Strong Biotechnologies's valuation (P/E 30.2x, P/B 1.7x), profitability (net margin 15.5%), revenue (¥1.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Strong Biotechnologies's market cap?
Beijing Strong Biotechnologies (300406) has a market capitalization of approximately ¥6.6B, trading at ¥11.19 on the SHZ. Market cap moves with the live share price.
What is Beijing Strong Biotechnologies's P/E ratio?
Beijing Strong Biotechnologies's trailing twelve-month P/E ratio is 30.2x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Strong Biotechnologies?
Beijing Strong Biotechnologies runs a net profit margin of 15.5%, a gross margin of 79.6%, and an operating margin of 19.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Strong Biotechnologies generate?
Beijing Strong Biotechnologies reported revenue of ¥1.4B for fiscal year 2025, with net income of ¥190M and earnings per share (EPS) of 0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Strong Biotechnologies pay a dividend?
Beijing Strong Biotechnologies offers a trailing dividend yield of about 10.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing Strong Biotechnologies financially healthy?
Beijing Strong Biotechnologies carries a debt-to-equity ratio of 0.28x and a current ratio of 12.18x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Strong Biotechnologies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Strong Biotechnologies (300406) the key facts are: market cap ¥6.6B, P/E 30.2x, revenue ¥1.4B, 52-week range 10.52-16.05. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Strong Biotechnologies's full fundamentals live
Get Beijing Strong Biotechnologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.